← Leaderboards
Michael F. Para
Ohio State University
$541,747
Attributed
$541,747
Total exposure
9
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $10.5K · FY2005–08$20K$15K$10K$5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$541,747 · 9
By mechanism
M01$541,747 · 8
N01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Abigail Norris Turner$2,687,785
- Julianne M Serovich$8,023,119
- Young C Lin$2,452,599
- Jose A. Bazan$1,450,041
- Ana M Mercado$154,325
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHiv InfectionsClinical ResearchAids TherapyHuman Therapy EvaluationAntiaids AgentProtease InhibitorLongitudinal Human StudyPharmacokineticsBloodSalivaCombination ChemotherapyUrineNelfinavirBlood ChemistryEfavirenzPatient /Disease RegistryDrug Screening /EvaluationDrug InteractionsHuman Immunodeficiency VirusHuman Immunodeficiency Virus 1Human TissueHealth Science Research SupportAmprenavir
Grant awards (15)
CLINICAL TRIAL: TREATMENT OF INADEQUATE CD4+ LYMPHOCYTE RECOVERY$10,492
M01 · FY2008 · RR · contact PI
ACTG 5177: AN OBSERVATIONAL STUDY OF PHARMACOKINETICS$5,199
M01 · FY2006 · RR · contact PI
ACTG 5177: AN OBSERVATIONAL STUDY OF PHARMACOKINETICS$6,728
M01 · FY2005 · RR
ACTG A5043: PHARMACOKINETIC INTERACTION STUDIES OF APV$30,661
M01 · FY2004 · RR
Intensive PK Study Of Lopinavir/Ritonavir And GW433908$3,679
M01 · FY2004 · RR
ESTABLISHMENT OF PATIENT COHORT FOR OHIO STATE UNIV AIDS CLINICAL TRIALS$193,916
M01 · FY2001 · RR
DELAVIRIDINE MESYLATE IN COMBINATION WITH ZIDOVUDINE &2 DOSES LAMIVUDINE$193,916
M01 · FY2001 · RR
PHASE II, RANDOMIZED, OPEN LABEL, COMPARATIVE TRIAL OF SALVAGE ANTIRETROVIRAL$0
M01 · FY2001 · RR
DELAVIRIDINE MESYLATE IN COMBINATION WITH ZIDOVUDINE &2 DOSES LAMIVUDINE$48,578
M01 · FY2000 · RR
ESTABLISHMENT OF PATIENT COHORT FOR OHIO STATE UNIV AIDS CLINICAL TRIALS$48,578
M01 · FY2000 · RR
PHASE II, RANDOMIZED, OPEN LABEL, COMPARATIVE TRIAL OF SALVAGE ANTIRETROVIRAL$0
M01 · FY2000 · RR
PHASE II, RANDOMIZED, OPEN LABEL, COMPARATIVE TRIAL OF SALVAGE ANTIRETROVIRAL$0
M01 · FY2000 · RR
CLINICAL CENTER$0
N01 · FY2000 · HB
ESTABLISHMENT OF A PATIENT COHORT FOR THE AIDS CLINICAL$0
M01 · FY2000 · RR
ESTABLISHMENT OF A PATIENT COHORT FOR THE AIDS CLINICAL$0
M01 · FY2000 · RR